DocMorris AG / Key word(s): AGMEGM Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich 02.05.2024 / 18:45 CET/CEST Frauenfeld, 2 May 2024   Press release Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich The shareholders approved the annual report and consolidated and statutory financial statements for 2023 and the Board of Directors’ proposal for the appropriation of the balance sheet result 2023. Discharge was granted to all members of the Board of Directors and the Executive Board. All members of the Board of ..read more

EQS-News: MEDICLIN AG / Key word(s): Expansion/Contract MEDICLIN: Transfer of operations of Reha-Klinik am Sendesaal to MEDICLIN took place on 1 May 02.05.2024 / 17:14 CET/CEST The issuer is solely responsible for the content of this announcement. Offenburg, 2 May 2024 MEDICLIN: Transfer of operations of Reha-Klinik am Sendesaal to MEDICLIN took place on 1 May Offenburg, 2 May 2024: On 1 May, the operation of the Reha-Klinik am Sendesaal was transferred to MEDICLIN. A symbolic handover of the key between MEDICLIN COO Thomas Piefke, clinic managing director and regional managing director Hol ..read more

EQS-News: Rentschler Biopharma SE / Key word(s): Personnel Rentschler Biopharma Appoints Patrick Cushing as VP Operations for U.S. Subsidiary 02.05.2024 / 14:10 CET/CEST The issuer is solely responsible for the content of this announcement. Rentschler Biopharma Appoints Patrick Cushing as VP Operations for U.S. Subsidiary   Laupheim, Germany, Milford (MA), USA, and Stevenage, UK, May 2, 2024 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that Patrick Cushing, Ph.D., has been promoted to Vic ..read more

EQS-News: MEDICLIN AG / Key word(s): Quarterly / Interim Statement MEDICLIN increases consolidated sales and operating result in the first quarter of 2024 02.05.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. Offenburg, 2 May 2024 MEDICLIN increases consolidated sales and operating result in the first quarter of 2024 MEDICLIN increases its consolidated sales for the first quarter of 2024 by 4.9% to EUR 185.4 million  Group EBIT of EUR 4.1 million significantly higher than in the same period of the previous year (EUR -1.7 million) Capacity u ..read more

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE 02.05.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement.   _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF       PRESS RELEASE   PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE   Vancouver, BC, Canada, May 1st, 2024 ..read more

EQS-News: Formycon AG / Key word(s): Quarterly / Interim Statement/Conference Formycon hosts conference call on the results of the first quarter 2024 02.05.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // May 02, 2024 Formycon hosts conference call on the results of the first quarter 2024 Planegg-Martinsried – Formycon AG (FWB: FYB, ‘Formycon’) today announced details of the conference call to release the results of the first quarter 2024 on May 08, 2024. The management board will discuss the company’s developments and key financ ..read more

AEVIS VICTORIA SA / Key word(s): Miscellaneous 02-May-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Fribourg, 2 May 2024 AEVIS VICTORIA SA (AEVS.SW) – Revenues from operating divisions are increasing, with positive forecasts for the current year. Growth for 1Q2024 is 7.2%. AEVIS VICTORIA SA (AEVIS) reported consolidated revenues for the first quarter of 2024 of CHF 281.9 million (1Q2023: CHF 263.0 million), an increase of 7.2%. AEVIS’s operating ..read more

, 05/01/2024 / 15:53, EST/EDT – EQS Newswire – Tryp Therapeutics Inc. (Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Canadian Stock Exchange, Nasdaq OTC) KELOWNA, BC / ACCESSWIRE / May 1, 2024 / Tryp Therapeutics, Inc. (“Tryp” or the “Company“) (CSE:TRYP)(OTCQB:TRYPF) and Exopharm Limited ACN 163 765 991 (“Exopharm“) are pleased to announce that completion of the previously announced plan of arrangement (the “Arrangement“) effective today, whereby Exopharm acquired Tryp in an all stock transaction by way of court-approved plan of arrangement under ..read more

Issuer: Immunic AG / Key word(s): Miscellaneous 01.05.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement.  Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update  – Webcast to be Held at 8:00 am ET on May 8, 2024 – NEW YORK, May 1, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release ..read more

Vitruvia Medical AG / Key word(s): Annual Results/Annual Report Vitruvia Medical AG: Year End results as of December 31, 2023 01-May-2024 / 08:36 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Vitruvia Medical AG: Year End results as of December 31, 2023 Anglikon, May 1st , 2024: Vitruvia Medical AG achieved a result after taxes of CHF -243,864.40 in the past year 2023 compared to CHF -1,095,349.38 in the previo ..read more